SLC25A17

Across TCGA pan-cancer cohorts, SLC25A17 RNA differs between tumor and matched normal tissue in 16 of 18 cancer types tested, making tumor–normal expression one of SLC25A17’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where SLC25A17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLC25A17 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

HNSC, THCA, and BLCA are the cancer types where SLC25A17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC25A17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	+1.161	<.001	11	view →
THCA	All	IV	−0.817	<.001	11	view →
BLCA	All	III,IV	+0.971	<.001	10	view →
LUAD	Female	All	+0.565	<.001	10	view →
STAD	All	II,III,IV	+0.766	<.001	9	view →
LIHC	All	III,IV	+0.608	<.001	9	view →
LUSC	Female	All	+0.902	<.001	7	view →
READ	All	All	+0.751	<.001	7	view →
COAD	Female	II,III,IV	+0.664	<.001	7	view →
KICH	Female	All	−0.811	<.001	6	view →
BRCA	All	III,IV	+0.676	<.001	6	view →
CHOL	Male	All	+1.231	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 16 lineages.

SLC25A17–HNSC

Open the HNSC breakdown →